Intravenous and subcutaneous administration of trastuzumab in a patient on peritoneal dialysis

Br J Clin Pharmacol. 2021 Aug;87(8):3372-3374. doi: 10.1111/bcp.14731. Epub 2021 Jan 19.

Authors

Stefania Kokkali^{1

2}, David Ternant³, Véronique Kemmel⁴, Dominique Levêque⁵, Fréderique Wendling¹, Philippe Barthelemy¹, Jean-Emmanuel Kurtz¹

Affiliations

¹ Department of Medical Oncology, Strasbourg University Hospital, Strasbourg, France.
² First Medical Oncology Department, Saint-Savvas Anticancer Hospital, Athens, Greece.
³ Department of Medical Pharmacology, CHRU de Tours, Tours University Hospital, Tours, France.
⁴ Biochemistry and Molecular Biology Department, Strasbourg University Hospital, Strasbourg, France.
⁵ Pharmacy Department, Strasbourg University Hospital, Strasbourg, France.

PMID: 33464605
DOI: 10.1111/bcp.14731

No abstract available

Publication types

Letter

MeSH terms

Administration, Intravenous
Humans
Peritoneal Dialysis* / adverse effects
Receptor, ErbB-2*
Trastuzumab / adverse effects

Substances

Receptor, ErbB-2
Trastuzumab